Otoprotective effect of MnTBAP in cisplatin-induced hearing loss
- 1Institute of Environmental Health Sciences, Wayne State University, Detroit, Michigan, United States of America
- 2Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan, United States of America
Abstract
Objective: Cisplatin, a life-saving chemotherapeutic drug, causes ototoxicity. Although sodium thiosulfate is used to prevent ototoxicity in pediatric patients, no other intervention has been approved for clinical use against cisplatin-induced hearing loss. Hence, there is an urgent need to identify drugs that prevent cisplatin ototoxicity. Methods: CBA/J mice were treated with cisplatin (3 mg/kg, i.p., daily for 5 days), and MnTBAP (10 mg/kg, i.p., daily for 8 days) was used to inhibit cisplatin-induced ototoxicity. Auditory brainstem responses (ABRs) and distortion product otoacoustic emissions (DPOAEs) were recorded before and after treatment to assess hearing loss, while immunohistochemistry with anti-Myosin-VIIa was conducted to examine hair cell loss, with phalloidin to examine spiral ganglion neuron (SGN) loss, and with anti-nitrotyrosine to assess nitrotyrosine levels. Results: Cisplatin treatment elevated the nitrotyrosine levels in hair cells and SGNs and increased the loss of these cells in the middle and basal cochlear regions. A negative correlation was observed between cisplatin-induced changes in the hair cell count or SGN density and nitrotyrosine levels. Cisplatin treatment elevated the hearing thresholds, as indicated by the ABRs, and lowered the DPOAE amplitudes, suggesting cisplatin-induced hearing loss. However, MnTBAP cotreatment prevented the cisplatin-induced changes in hearing sensitivity and reversed the morphological changes. Conclusion: The otoprotection observed with MnTBAP cotreatment along with the attenuation of cisplatin-induced increase in nitrotyrosine levels in the cochlea indicates its potential as an inhibitor of cochlear nitrative stress and its utility in mitigating cisplatin-induced ototoxicity.
Related
- Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review
- Central relaxin-3/RXFP3 signaling potently drives orexigenic behaviors and attenuates cisplatin-induced anorexia and body weight loss
- Trends and burden of occupational noise-induced hearing loss in Türkiye: evidence from the national occupational disease registry
- Occupational Noise-Induced Hearing Loss in Indian Black Tea-Processing Factories: Assessing the Prevalence and Associated Factors of an Overlooked Problem
- A Delphi consensus recommendations from China for the management of radiation-induced hearing loss in patients with nasopharyngeal carcinoma.
BibTeX
@article{mehmood2026otoprotective,
title = {{Otoprotective effect of MnTBAP in cisplatin-induced hearing loss}},
author = {Shomaila Mehmood and Pankaj Bhatia and Samson Jamesdaniel},
journal = {PLOS One},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0351911},
url = {https://doi.org/10.1371/journal.pone.0351911},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Otoprotective effect of MnTBAP in cisplatin-induced hearing loss
AU - Shomaila Mehmood
AU - Pankaj Bhatia
AU - Samson Jamesdaniel
PY - 2026
DA - 2026/09/21
JO - PLOS One
DO - 10.1371/journal.pone.0351911
UR - https://doi.org/10.1371/journal.pone.0351911
AB - Objective: Cisplatin, a life-saving chemotherapeutic drug, causes ototoxicity. Although sodium thiosulfate is used to prevent ototoxicity in pediatric patients, no other intervention has been approved for clinical use against cisplatin-induced hearing loss. Hence, there is an urgent need to identify drugs that prevent cisplatin ototoxicity. Methods: CBA/J mice were treated with cisplatin (3 mg/kg, i.p., daily for 5 days), and MnTBAP (10 mg/kg, i.p., daily for 8 days) was used to inhibit cisplatin-induced ototoxicity. Auditory brainstem responses (ABRs) and distortion product otoacoustic emissions (DPOAEs) were recorded before and after treatment to assess hearing loss, while immunohistochemistry with anti-Myosin-VIIa was conducted to examine hair cell loss, with phalloidin to examine spiral ganglion neuron (SGN) loss, and with anti-nitrotyrosine to assess nitrotyrosine levels. Results: Cisplatin treatment elevated the nitrotyrosine levels in hair cells and SGNs and increased the loss of these cells in the middle and basal cochlear regions. A negative correlation was observed between cisplatin-induced changes in the hair cell count or SGN density and nitrotyrosine levels. Cisplatin treatment elevated the hearing thresholds, as indicated by the ABRs, and lowered the DPOAE amplitudes, suggesting cisplatin-induced hearing loss. However, MnTBAP cotreatment prevented the cisplatin-induced changes in hearing sensitivity and reversed the morphological changes. Conclusion: The otoprotection observed with MnTBAP cotreatment along with the attenuation of cisplatin-induced increase in nitrotyrosine levels in the cochlea indicates its potential as an inhibitor of cochlear nitrative stress and its utility in mitigating cisplatin-induced ototoxicity.
SN - 1932-6203
ER -